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Abstract
Objective:
The objective of this study was to evaluate the effectiveness of 3-factor prothrombin complex concentrate
(3F-PCC) compared to 4-factor PCC (4F-PCC) in warfarin-associated bleeding.
Methods:
This multicenter, retrospective, cohort study analyzed data from patients admitted between May 2011 and
October 2014 who received PCC for warfarin-associated bleeding. The primary outcome was the rate of
international normalized ratio (INR) normalization, defined as an INR ≤1.3, after administration of 3F-PCC
compared to 4F-PCC. Other variables of interest included the incidence of additional reversal agents, new
thromboembolic events, and mortality.
Results:
A total of 134 patients were included in the analysis. The average dose of PCC administered was 24.6 ± 9.3
units/kg versus 36.3 ± 12.8 units/kg in the 3F-PCC and 4F-PCC groups, respectively, P < 0.001. Baseline
INR in the 3F-PCC and 4F-PCC groups was 3.61 ± 2.3 and 6.87 ± 2.3, respectively P < 0.001. 4F-PCC had
a higher rate of INR normalization at first INR check post-PCC administration compared to 3F-PCC
(84.2% vs. 51.9%, P = 0.0001). Thromboembolic events, intensive care unit and hospital length of stay, and
mortality were similar among both groups.
Conclusion:
The use of 4F-PCC leads to a more significant reduction in INR compared to 3F-PCC though no difference
in mortality or length of stay was observed. Thromboembolism rates were similar among both groups.
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INTRODUCTION
Warfarin is a commonly used anticoagulant for the treatment of a variety of indications, most commonly
deep vein thromboembolism, pulmonary embolism, and atrial fibrillation. Because warfarin has a narrow
therapeutic window and interindividual dosing variability, bleeding events are of high concern with the
incidence of major bleeding events reported between 0% and 10%.[1,2] Emergency medicine physicians
are often the first to evaluate patients on warfarin presenting with major bleeding. They make crucial
treatment decisions including both if and how to reverse the anticoagulation effects of warfarin. While the
mainstay of therapy for most warfarin-associated bleeding events is Vitamin K and fresh frozen plasma
(FFP), prothrombin complex concentrate (PCC) is often utilized in cases of major or life-threatening
bleeding.[3,4]
Warfarin exerts its anticoagulant effect by inhibiting the Vitamin K-dependent clotting factors II, VII, IX,
and X.[5] The administration of PCC negates the anticoagulant effects of warfarin by quickly replenishing
these clotting factors. Before 2013, only 3-factor PCC (3F-PCC) was available in the United States (US).
Four-factor PCC (4F-PCC) has been available to providers in the US since May 2013 and is the only
product to carry the Food and Drug Administration (FDA)-labeled indication of warfarin reversal. Both
PCC formulations contain approximately 25 times the amount of factors II, IX, and X found in plasma.
Four-factor PCC is unique in that it also contains ample amounts of factor VII.[3]
Despite the lack of an FDA approved indication for warfarin reversal, common practice in the US before
2013 had evolved from FFP to 3F-PCC for reversal of severe warfarin-associated bleeding, as well as
bleeding from other types of oral anticoagulant therapy. After the FDA approval of 4F-PCC for urgent
reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist therapy (e.g., warfarin),
many institutions and medical societies including the American College of Chest Physicians have begun to
favor 4F-PCC.[6] Unfortunately, there are limited comparative data to determine what, if any, difference in
safety or efficacy exists between PCC formulations. The purpose of this study is to evaluate the
effectiveness of 3F-PCC compared to 4F-PCC in warfarin-associated bleeding.
METHODS
Study design and setting
This was a multicenter, retrospective, cohort study conducted from May 2011 to September 2014 at five
institutions in the US. All participating institutions received approval from their respective Investigational
Review Boards. All patients receiving 3F-PCC or 4F-PCC for warfarin-associated bleeding within the
study period were included in the analysis. Patients who were <18 years of age, pregnant, or prisoners were
excluded from the study. Use of either 3F-PCC or 4F-PCC was based on each institution's medication
formulary, therapeutic guideline, or provider discretion. All formulations were also dosed based on each
institution's guideline, all of which round to the nearest vial size of the specific factor product. Baseline
demographic information was collected and included age, sex, weight, indication for anticoagulation,
baseline International normalized ratio (INR), bleed location, Acute Physiology and Chronic Health
Evaluation II score,[7] and injury severity score for trauma admissions.[8]
Outcomes
The primary outcome was to compare the effectiveness of 3F-PCC versus 4F-PCC for the reversal of acute
bleeding in patients on warfarin therapy. Effective reversal was defined as attainment of INR ≤1.3.
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Secondary outcomes included the mean value and time of first INR post-PCC administration, mean INR
value of any additional samples taken within 24 h post-PCC administration, incidence of additional
anticoagulation reversal agents utilized, incidence of surgery within 12 h of PCC administration, and
incidence of mortality. Safety was assessed by evaluation of the incidence of new thromboembolism within
7 days of PCC administration as determined by radiology report and/or physician documentation.
Statistical analysis
The sample size calculation was based on historical data with a predetermined alpha at 0.05 and beta of 0.8.
To reach significance, a total of 266 patients (133 per group) were needed to be analyzed. Data was
presented in percentage or mean ± standard deviation. Dichotomous data were compared using Chi-square
or Fisher's exact test. All continuous data were normally distributed and analyzed with the Student's t-test.
RESULTS
Characteristics of study subjects
A total of 134 patients met study inclusion. Of those included, 77 (57.5%) received 3F-PCC and 57
(42.5%) received 4F-PCC. Overall, baseline characteristics were similar among the 3F-PCC and 4F-PCC
groups [Table 1], with the exception of age (74 vs. 57 years; P = 0.013) and baseline INR (3.6 vs. 6.8; P <
0.001). In both groups, the main indications for anticoagulation were atrial fibrillation and treatment of
venous thromboembolic disease.
Main results
Of the patients receiving 4F-PCC, 84.2% achieved an INR ≤1.3 compared to 51.9% (P < 0.001) in those
receiving 3F-PCC. Over 90% of patients in both groups received Vitamin K in addition to PCC (96.5% 4F-
PCC vs. 90.9% 3F-PCC). The mean time to initial INR after PCC administration was 3.3 ± 0.10 h in the
4F-PCC group versus 3.8 ± 0.12 h in the 3F-PCC group (P = 0.32). The mean initial INR after 4F-PCC
administration was 1.25 ± 0.33 and 1.40 ± 0.27 after 3F-PCC (P = 0.009). In those with additional INR
values obtained within 24 h of administration, 78% of patients who received 4F-PCC and 73% who
received 3F-PCC reached an INR ≤1.3. Mean INR in those with additional INR values was 1.23 ± 0.42
with 4F-PCC and 1.25 ± 0.18 with 3F-PCC, which did not meet statistical significance (P = 0.79).
The mean PCC dose was 36.3 ± 12.8 units/kg for patients receiving 4F-PCC and 24.6 ± 9.3 units/kg for
those receiving 3F-PCC. The extent of INR reversal between the two groups broken down by PCC dose
can be found in Table 2. The majority of patients in both groups received intravenous phytonadione (87.7%
4F-PCC vs. 96.7% 3F-PCC). Patients with a baseline INR >4 were more likely to reach goal INR in the 4F-
PCC group compared to 3F-PCC (84.4% vs. 40%; P = 0.003). Similarly, more patients receiving 4F-PCC
reached goal INR when baseline INR was <4 (84.0% vs. 56.1%; P = 0.03). Three patients received an
additional dose of PCC in the 3F-PCC group and one patient received Factor VII in the 4F-PCC group. FFP
was given to 17.5% of patients receiving 4-PCC and 51.9% in those receiving 3-PCC (P ≤ 0.01). When
excluding patients who received FFP, the results were similar to the overall findings. Of those receiving 4F-
PCC but no FFP, 82.9% achieved an INR ≤1.3 compared to 56.7% in those receiving 3F-PCC and no FFP
(P = 0.01).
There was no difference in intensive care unit (5.8 vs. 6.7 days, P = 0.59) or hospital length of stay (9.0 vs.
11.6 days, P = 0.28), incidence of surgery within 12 h (80.7% vs. 84.2%, P = 0.60), or mortality (21.4% vs.
17.1%, P = 0.65) between the 4F-PCC and 3F-PCC groups. Two patients in each group developed a new
thromboembolism within 7 days of PCC administration.
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DISCUSSION
In this study, 4F-PCC appears to be more effective at lowering INR to ≤1.3 within 4 h of administration
although this effect ultimately had no impact on length of stay or mortality. These results are similar to a
single-center study of 53 patients conducted by Al-Majzoub et al. Their retrospective study noted a higher
percentage of patients achieving INR reversal with approximately 26 units/kg of 4F-PCC and 3F-PCC
(83.3% vs. 42.9%, P < 0.01) with a similar length of stay and mortality rate.[9] Our study expands on these
findings but provides increasing external validity by expanding the sample size and utilizing multiple
centers, each with their own warfarin reversal protocols and dosing strategies.
When assessing efficacy of reversal agents for warfarin-associated bleeding, the ability of the intervention
to reverse INR is often utilized as the primary outcome. As previously mentioned, warfarin affects multiple
clotting factors, all with varying half-lives. Factor VII has the shortest plasma half-life (5 h) whereas the
other affected clotting factors have half-lives between 15 and 65 h.[10] The INR is an imperfect marker of
warfarin coagulopathy due to its differing sensitivity for the warfarin clotting factors. The INR assay
measures activity of the extrinsic (factor VII) and common pathways (factor II and X) but not the intrinsic
pathway (factor IX). Reagents used for the assay are most sensitive to factor VII so the presence or absence
of factor VII will have the largest impact on the INR, whereas factor X and II will have a smaller impact,
and factor IX no impact. The short half-life of factor VII, along with the variation of clotting factors found
in PCC products can impact the INR. Using INR as an end point to assess efficacy of warfarin reversal is
advantageous because it provides an objective endpoint, yet it has never been shown to correlate with
improved outcomes.[11] While cessation of bleeding and improved clinical outcomes may be more
beneficial outcomes, these are much harder to objectively measure and often depend on physician opinion,
making them suboptimal for research studies.
In this study, an INR goal of 1.3 or less was used to determine the effectiveness of the reversal agents. An
INR value of 1.3 was chosen based on previous PCC studies.[9,12] One can argue using an INR of 1.3 is an
arbitrary goal and many surgeons often use a higher INR threshold of <1.5 or 1.7 when determining
whether or not to perform a procedure. This should be considered for any future studies looking at INR
reversal in warfarin-associated bleeding. In the current study, an INR of <1.7 occurred in 94% receiving
4F-PCC and 87% receiving 3F-PCC (P = 0.149). This INR target may be an acceptable indicator of
successful reversal to most clinicians and may have been a more clinically relevant endpoint.
Another element to consider when comparing outcomes is the difference in dosing strategies between the
two groups. The mean dose of 3F-PCC administered was more conservative than most dosing
recommendations with many sources recommending closer to 35–50 units/kg.[13,14] Of the 3F-PCC group
dosed at 30 units/kg or greater in our study, 64.7% had an INR ≤1.3 compared to 44.2% of those receiving
<30 units/kg. In addition to the 3F-PCC dose being on the lower end of the recommended dose, it was also
12 units/kg less on average than 4F-PCC which may have also had a clinical impact on outcomes.
Patients receiving 3F-PCC and 4F-PCC are at increased risk of thromboembolism from reversal of
anticoagulation in a patient with an underlying hypercoagulability state and through supplementation of
clotting factors that promote clot formation. The larger factor VII content of 4F-PCC compared to 3F-PCC
has been theorized to put patients at higher risk for clot development. Our study showed similar rates of
thromboembolism within each group. In patients receiving 3F-PCC, one patient developed a deep vein
thrombosis, and one was found to have an upper subclavian clot. In those receiving 4F-PCC, one patient
had an ischemic stroke and one developed a deep vein thrombosis.
There is a significant cost increase associated with 4F-PCC compared to 3F-PCC. When determining
formulary status of medications at an institution, one must first focus on efficacy and safety and then, only
if those aspects are deemed similar, cost must also be utilized in the decision of which agent to carry.
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Despite the lack of head-to-head trials comparing the two PCC formulations for anticoagulation reversal,
many hospitals have switched their formulary agent to 4F-PCC because of its additional factor VII content
and the theoretical benefit it encompasses. Because there are no prospective comparative trials, it is yet to
be determined if the more rapid INR reversal observed with 4F-PCC truly improves clinical outcomes over
3F-PCC to justify the routine use of a more expensive agent with a potential for higher thrombotic events.
Limitations
While one strength of this study is that its external validity was increased because it was conducted at
multiple, nonassociated institutions, this also provides limitations. Each institution has its own
anticoagulation reversal guidelines that utilize different PCC dosing recommendations which could lead to
varying strategies for reversal. There was no standardization in the time of INR collection after PCC
administration though time of collection appeared similar among both groups. This study was also
retrospective in nature which prevents the ability to standardize the reversal approach to ensure equivalent
timing, dosing strategy, and concomitant therapies, whereas also requiring investigators to rely on historical
charting for data collection. Despite the small number of patients and potential impact on power, the
sample size was sufficient to demonstrate a significant difference in the primary outcome, achievement of
target INR. As previously mentioned, INR has not been shown to correlate with improved clinical
outcomes and may not be the best end point to determine the effectiveness of the reversal agents.
CONCLUSION
Patients receiving 4F-PCC had a more significant reduction in INR when compared to 3F-PCC though this
did not result in a decrease in the length of stay or mortality. The rate of thromboembolism was small and
similar among both groups.
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Table 1
Baseline Characteristics*
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Table 2
INR Reversal Based on PCC Dose
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